-
-
Fenofibrate for Diabetic Retinopathy, Does Obesity Cause A Delay in Diagnosis of Prostate Cancer?, and Protecting Bone During Glucocorticoid Treatment
-
The FDA has approved, by priority review, the first drug to help manage patients with phenylketonuria (PKU).
-
Absent or low testosterone levels in men appear to have a pathogenic role in the development of cardiovascular disease resulting in increased cardiovascular and all-cause mortality and are not simply "markers" for illness or wellness.
-
Patients with mild-to-moderate obstructive sleep apnea (OSA) who were treated with Continuous Positive Airway Pressure (CPAP) experienced an absolute risk reduction in cardiovascular risk compared with those who were not treated.
-
The number, type, and severity of comorbidities are important determinants of diabetes self-care.
-
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
FDA warnings for existing drugs dominate pharmaceutical news this month.